Navigation Links
Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
Date:8/15/2012

Researchers at Moffitt Cancer Center, working with colleagues in Sweden, the Netherlands and Puerto Rico, have validated a radiosensitivity molecular signature that can lead to better radiation therapy decisions for treating patients with breast cancer.

The results appeared in a recent issue of Clinical Cancer Research, a publication of the American Association for Cancer Research.

The study examined patients with breast cancer who had been treated with radiation therapy and demonstrated that a radiosensitivity molecular signature (RSI) could predict clinical outcomes exclusively in patients treated with radiation therapy. The radiosensitivity molecular signature (RSI) used by the research team had previously been tested and validated for rectal, esophageal, and head and neck cancers. The technology, which identifies radiosensitivity and radioresistance, opens the door to biologically guided radiation therapy and offers the potential for better outcomes.

"Developing a radiosensitivity predictive assay has been a goal of radiation biology for decades," said Javier F. Torres-Roca, M.D., member of the Experimental Therapeutics program at Moffitt. "This effort supports the emphasis on personalized medicine, where the goal is to use molecular signatures to guide therapeutic decisions."

According to Torres-Roca, approximately 60 percent of all cancer patients receive radiation therapy during their treatment. Yet until now, no molecular diagnostic or biomarker of radiosensitivity had been developed to predict its benefit.

The radiosensitivity molecular signature was developed based on gene expression for 10 specific genes and a linear regression algorithm. RSI was developed in 48 cancer cell lines using a systems-biology strategy focused on identifying biomarkers for cellular radiosensitivity.

This study validated RSI's benefit when researchers found that radiosensitive breast cancer patients had an improved five-year, relapse-free survival when compared to radioresistant patients.

"This study validated RSI in 503 patients in two independent data sets," Torres-Roca said. "We have validated RSI in five independent cohorts totaling 621 patients, so this latest validation study, to the best of our knowledge, makes this technology the most extensively validated molecular signature in radiation oncology."

The successful transition from applying the technology to cell lines to patient application also suggests that the biological basis of cellular radiosensitivity is conserved between cell lines and patients and also across epithelial tumors, Torres-Roca said.

"We propose that RSI is a predictive biomarker of radiation therapy therapeutic benefit for patients with breast cancer," Torres-Roca said. "This novel biomarker provides an opportunity to integrate individual tumor biology with clinical decision-making in radiation oncology."


'/>"/>
Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
2. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
3. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
4. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
5. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
6. Moffitt researchers find cutaneous human papillomavirus infection a risk factor for skin cancer
7. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
8. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
9. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
10. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
11. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that ... you are not alone. According to the Center for Disease Control and Prevention (CDC), ... 2 diabetes and certain types of cancer, some of the leading causes of preventable ...
(Date:2/8/2016)... Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired ... also was the American Cancer Society’s 2015 CEO of the Year , helped ...
(Date:2/8/2016)... ... , ... Discover the Rocky Mountain region’s longest running and impressive garden and ... also get to see the most incredible gardens and home improvement experts that attend ... Colorado Convention Center - 700 14th St. Denver CO, is an exciting event that ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is ... 11th, 2016 in honor of his birthday on February 10th. During this time, ... Trivedi is known by over 250,000 people from over 40 different countries as an ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb.8, 2016 Alzheimer Diagnostic Tests - ... Medical Devices sector report , "Alzheimer Diagnostic ... an overview of Alzheimer Diagnostic Tests currently in ... on the pipeline products with comparative analysis of ... report reviews major players involved in the pipeline ...
(Date:2/8/2016)... 2016 Cardiovascular Surgery Devices - Medical ... Medical Devices sector report, "Cardiovascular Surgery Devices - ... of Cardiovascular Surgery Devices currently in pipeline stage. ... The report provides comprehensive information on the pipeline ... various stages of development. The report reviews major ...
(Date:2/8/2016)... NEW YORK , Feb. 8, 2016 /PRNewswire/ ... market, today announces its first male sexual enhancement ... enhancement, EnduramenT combines proven ethnobotanicals with a patented ... of nitric oxide, the chemical compound responsible for ... Forgoing the ...
Breaking Medicine Technology: